Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome

Journal of Obstetrics and Gynaecology Research

Volumn 40, Issue 5, 2014, Pages 1353-1360

  Genazzani, Alessandro D ^a   Santagni, Susanna ^a   Ricchieri, Federica ^a   Campedelli, Annalisa ^a   Rattighieri, Erika ^a   Chierchia, Elisa ^a   Marini, Giulia ^a   Despini, Giulia ^a   Prati, Alessia ^a   Simoncini, Tommaso ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

C reactive protein; Hyperinsulinism; Insulin resistance; Myo inositol; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; BROMELAIN; C REACTIVE PROTEIN; ESTRADIOL; FOLLITROPIN; INOSITOL; INSULIN; LACTOFERRIN; LUTEINIZING HORMONE; PROGESTERONE; REDESTOP; UNCLASSIFIED DRUG; GONADORELIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; FEMALE; GONADORELIN TEST; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LUTEINIZING HORMONE RELEASE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; TRANSVAGINAL ECHOGRAPHY; GLUCOSE TOLERANCE TEST; METABOLISM; POLYCYSTIC OVARY SYNDROME; SECRETION (PROCESS);

BODY WEIGHT; C-REACTIVE PROTEIN; FEMALE; GLUCOSE TOLERANCE TEST; GONADOTROPIN-RELEASING HORMONE; HUMANS; INOSITOL; INSULIN; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME;

EID: 84903576399     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12319     Document Type: Article

References (39)

1. Homburg R. Polycystic ovary syndrome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996; 11: 29-39. (Pubitemid 26047668)
2. Morgante G, Orvieto R, Di Sabatino A, Musacchio MC, De Leo V. The role of inositol supplementation in patients with polycycstic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril 2011; 95: 2642-2644.
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycycstic ovary syndrome. Fertil Steril 2004; 81: 19-25.
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
5. Ciampelli M, Fulghesu AM, Cucinelli F et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999; 48: 167-172. (Pubitemid 29072269)
6. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114-119. (Pubitemid 38058335)
7. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-Chiro-Inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29: 300-305. (Pubitemid 44106508)
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800. (Pubitemid 28009567)
9. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007; 23: 146-152. (Pubitemid 46570211)
10. Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health 2010; 6: 577-593.
11. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 2003; 327: 951-953.
12. Baillargeon JP, Nestler JE, Ostlund RE, Apridronize T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycycstic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008; 23: 1439-1446. (Pubitemid 351770579)
13. Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: A systematic review. Gynecol Endocrinol 2011; 27: 256-262.
14. Larner J. d-chiro-Inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3: 47-60. (Pubitemid 35174544)
15. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1993; 340: 1314-1320.
16. Papaleo E, Unfer V, Baillargeon J-P, Fusi F, Occhi F, deSantis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91: 1750-1754.
17. Baillargeon JP, Nestler JE. Commentary: Polycystic ovary syndrome: A syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006; 91: 22-24. (Pubitemid 43069109)
18. Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiroinositol to myoinositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002; 293: 1092-1098. (Pubitemid 34694154)
19. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 139-144. (Pubitemid 351365855)
20. Gerli S, Papaleo E, Ferrari A, di Renzo GC. Randomized, double blind placebo-controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007; 11: 347-354. (Pubitemid 350200349)
21. Papaleo E, Unfer V, Beillargeon JP et al. Myoinositol in patients with polycystic ovary syndrome a novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700-703. (Pubitemid 350261211)
22. Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 508-513.
23. Chikhale EG, Balbo A, Galdzicki Z, Rapoport SI, Shetty U. Measurement of myo-inositol turnover in phosphatidilinositol: Description of a model and mass spectrometric method for cultured cortical neurons. Biochemistry 2001; 40: 11114-111120.
24. Legro RS, Finegood D, Dunaif A. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694-2698. (Pubitemid 28493762)
25. Oerter KE, Guardabasso V, Rodabrd D. Detection and characterization of peaks and estimation of instantaneous secretory rate for episodic pulsatile hormone secretion. Comput Biomed Res 1986; 19: 170-191. (Pubitemid 16080306)
26. Genazzani AD, Chierchia E, Rattighieri E et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol 2010; 26: 684-689.
27. Veldhuis JD, Fraioli F, Rogol AG, Dufau ML. Metabolic clearance of biologically active luteinizing hormone in man. J Clin Invest 1986; 77: 1122-1127.
28. Genazzani AD, Petraglia F, Benatti R et al. Luteinizing hormone secretory burst duration is independent from luteinizing hormone, prolactin or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab 1991; 72: 1220-1225. (Pubitemid 21921831)
29. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: A systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28: 509-515.
30. Asplin I, Galasko G, Larner J. d-chiro-inositol deficiency and insulin resistance:A comparison of the chiro-inositol-and the myo-inositolcontaining insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 1993; 90: 5924-5928. (Pubitemid 23191426)
31. Kennington AS, Hill CR, Craig J et al. Low urinary chiroinositol excretion in non-insulindependent diabetes mellitus. N Engl J Med 1990; 323: 373-378. (Pubitemid 20243903)
32. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28: 463-491. (Pubitemid 47236334)
33. Genazzani AD, Prati A, Santagni S et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012; 28: 969-973.
34. Kim JW, Han JE, Kim YS, Won HJ, Yoon TK, Lee WS. High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 259-263.
35. Verit FF. High sensitive serum-C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet 2010; 281: 1009-1014.
36. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 155: 65-71. (Pubitemid 34042434)
37. Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008; 31: 328-334. (Pubitemid 351213346)
38. Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2008; 126: 345-352.
39. Secor ER Jr, Singh A, Guernsey LA et al. Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. Int Immunopharmacol 2009; 9: 340-346.